Dilly Stephen George
Officer, Director at CDXS; Director at SGMO; President and CEO at Aimmune Therapeutics, Inc.
- Sold, on record
- $21.8M
- Dollars the filings state
- Form 4 sales
- 14
- Latest Mar 8, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- CDXSCODEXIS, INC.Officer, Director
- SGMOSANGAMO THERAPEUTICS, INCDirector
- Aimmune Therapeutics, Inc.President and CEO
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Aimmune Therapeutics, Inc.750,000 shares
- CDXS55,075 shares
- SGMO50,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Aimmune Therapeutics, Inc.Plan not statedOct 16 2017
Sold 1,154 shares at $26.24 ($30k)
Dilly Stephen George, President and CEO
Sold 0.3% of holdings ($10.9M position)415,308 shares left0x usual sizeFiling
- 2 Form 4 sale Aimmune Therapeutics, Inc.Plan not statedOct 23 +7 days
Sold 100,000 shares at $33.54 ($3.4M)
Dilly Stephen George, Officer, Director
Sold 24.1% of holdings ($13.9M position)315,308 shares left2x usual sizeFiling
- 3 Form 4 sale Aimmune Therapeutics, Inc.UnusualJun 5 +225 days
Sold 165,374 shares at $32.14 ($5.3M)
Dilly Stephen George, Officer, Director
Sold 34.4% of holdings ($15.4M position)315,308 shares left3.3x usual sizeFiling
- 4 Form 4 sale Aimmune Therapeutics, Inc.UnusualJun 8 +3 days
Sold 105,169 shares at $30.93 ($3.3M)
Dilly Stephen George, President and CEO
Sold 25% of holdings ($13M position)315,308 shares left2.1x usual sizeFiling
- 5 Form 4 sale Aimmune Therapeutics, Inc.Plan not statedJun 11 +3 days
Sold 29,457 shares at $30.83 ($908k)
Dilly Stephen George, President and CEO
Sold 8.5% of holdings ($10.6M position)315,308 shares left0.4x usual sizeFiling
- 6 Form 4 sale SGMOUnusualMar 16 +644 days
Sold 15,000 shares at $6.02 ($90k)
Dilly Stephen George, Director
Sold 75% of holdings ($120k position)5,000 shares leftFirst sale on recordFiling
- 7 Form 4 sale SGMOUnusualMar 19 +3 days
Sold 35,000 shares at $6.00 ($210k)
Dilly Stephen George, Director
Sold 87.5% of holdings ($240k position)5,000 shares leftFiling
- 8 Form 4 sale CDXSPlan not statedMar 8 +1084 days
Sold 55,075 shares at $4.58 ($252k)
Dilly Stephen George, Officer, Director
Sold 12.6% of holdings ($2M position)380,399 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (14)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 | CDXS | Officer, Director | Form 4 sale | 55,075 | $252k | 12.6% | Plan not stated | SEC |
| Mar 19, 2020 | SGMO | Director | Form 4 sale | 35,000 | $210k | 87.5% | Unusual | SEC |
| Mar 16, 2020 | SGMO | Director | Form 4 sale | 15,000 | $90k | 75.0% | Unusual | SEC |
| Jun 11, 2018 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 29,457 | $908k | 8.5% | Plan not stated | SEC |
| Jun 8, 2018 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 105,169 | $3.3M | 25.0% | Unusual | SEC |
| Jun 5, 2018 | Aimmune Therapeutics, Inc. | Officer, Director | Form 4 sale | 165,374 | $5.3M | 34.4% | Unusual | SEC |
| Oct 23, 2017 | Aimmune Therapeutics, Inc. | Officer, Director | Form 4 sale | 100,000 | $3.4M | 24.1% | Plan not stated | SEC |
| Oct 16, 2017 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 1,154 | $30k | 0.3% | Plan not stated | SEC |
| Oct 6, 2017 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 98,846 | $2.6M | 19.2% | Plan not stated | SEC |
| Sep 25, 2017 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 100,000 | $2.5M | 16.3% | Plan not stated | SEC |
| Jul 26, 2017 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 50,000 | $1.1M | 7.5% | Plan not stated | SEC |
| Jun 23, 2017 | Aimmune Therapeutics, Inc. | President and CEO | Form 4 sale | 49,400 | $998k | 6.9% | Plan not stated | SEC |
| May 10, 2017 | Aimmune Therapeutics, Inc. | Officer, Director | Form 4 sale | 600 | $12k | 0.1% | Plan not stated | SEC |
| Nov 11, 2016 | Aimmune Therapeutics, Inc. | Officer, Director | Form 4 sale | 50,000 | $1.3M | 6.5% | Plan not stated | SEC |